Your insights could help others on their journey to better health
The TRIUMPH-4 result of 28.7 percent at 68 weeks confirms what the Phase 2 curve already suggested: weight loss on retatrutide had not plateaued at 24 weeks
In short, while GLP-1s themselves dont inherently make you tired, the metabolic changes and side effects they trigger can lead to temporary fatigue for some users
The next few months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape, as experts anticipate several new indication decisions from the United States (U.S.) Food and Drug Administration (FDA), including for metabolic dysfunction-associated steatohepatitis (MASH) and the first orally administered GLP-1 medicines for chronic weight management
The quantity is then shot up as the weeks go by
13 Unlike the previous cardiovascular outcome trials (CVOTs) with GLP-1RAs where the majority of participants had established cardiovascular disease (73100%), in REWIND the majority of patients (68.5%) only had cardiovascular risk factors